The source records describe separate financial updates. NTT Docomo raised its fiscal 2026 operating-profit forecast by ¥20 billion to ¥963 billion and increased planned capital investment by ¥43 billion to ¥900 billion. Novo Nordisk raised its 2026 adjusted sales and adjusted operating-profit outlook to between 2% growth and a 2% decline at constant exchange rates after stronger-than-expected third-quarter results. The Danish drugmaker’s obesity-care sales rose 22% at constant exchange rates to 26.15 billion Danish kroner, while net sales reached 79.20 billion kroner. Adjusted operating profit increased 27% to 31.72 billion kroner, but reported operating profit fell 9% to 23.01 billion kroner because of 8.7 billion kroner in non-cash impairment charges. Novo Nordisk expects 2026 free cash flow of 60 billion to 70 billion kroner and plans to reduce U.S. wholesale acquisition prices for Wegovy and Ozempic to $675 from January 1, 2027.